Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
COVID-19
IgG
SARS-CoV-2
T-cell immune response
autoimmunity
disease modifying therapies (DMTs)
humoral response
multiple sclerosis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
02
2022
accepted:
04
03
2022
entrez:
18
4
2022
pubmed:
19
4
2022
medline:
20
4
2022
Statut:
epublish
Résumé
Immunomodulatory/immunosuppressive activity of multiple sclerosis (MS) disease modifying therapies (DMTs) might affect immune responses to SARS-CoV-2 exposure or vaccination in patients with MS (PwMS). We evaluated the effect of DMTs on humoral and cell-mediated immune responses to 2 and 3 vaccinations and the longevity of SARS-Cov-2 IgG levels in PwMS. 522 PwMS and 68 healthy controls vaccinated with BNT162b2-Pfizer mRNA vaccine against SARS-CoV-2, or recovering from COVID-19, were recruited in a nation-wide multi-center study. Blood was collected at 3 time-points: 2-16 weeks and ~6 months post 2 75% PwMS were seropositive post 2 PwMS treated with most DMTs developed humoral and T-cell responses following 2 and 3 mRNA SARS-CoV-2 vaccinations. Fingolimod- or ocrelizumab-treated patients had diminished humoral responses, and fingolimod compromised the cellular responses, with no improvement after a 3
Sections du résumé
Background
Immunomodulatory/immunosuppressive activity of multiple sclerosis (MS) disease modifying therapies (DMTs) might affect immune responses to SARS-CoV-2 exposure or vaccination in patients with MS (PwMS). We evaluated the effect of DMTs on humoral and cell-mediated immune responses to 2 and 3 vaccinations and the longevity of SARS-Cov-2 IgG levels in PwMS.
Methods
522 PwMS and 68 healthy controls vaccinated with BNT162b2-Pfizer mRNA vaccine against SARS-CoV-2, or recovering from COVID-19, were recruited in a nation-wide multi-center study. Blood was collected at 3 time-points: 2-16 weeks and ~6 months post 2
Results
75% PwMS were seropositive post 2
Conclusion
PwMS treated with most DMTs developed humoral and T-cell responses following 2 and 3 mRNA SARS-CoV-2 vaccinations. Fingolimod- or ocrelizumab-treated patients had diminished humoral responses, and fingolimod compromised the cellular responses, with no improvement after a 3
Identifiants
pubmed: 35432335
doi: 10.3389/fimmu.2022.868915
pmc: PMC9012137
doi:
Substances chimiques
COVID-19 Vaccines
0
Immunoglobulin G
0
RNA, Messenger
0
Vaccines, Synthetic
0
mRNA Vaccines
0
Fingolimod Hydrochloride
G926EC510T
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
868915Investigateurs
Lea Glass-Marmor
(L)
Anat Volkovitz
(A)
Sara Dishon
(S)
Zeev Dishon
(Z)
Netta Kugelman
(N)
Zeev Nitsan
(Z)
Marwan Alkrenawi
(M)
Nurit Hovel
(N)
Nir Michal
(N)
Vered Loew-Shavit
(V)
Lital Mizrahi
(L)
Marsel Zafrani
(M)
Panayiota Petrou
(P)
Nour Eddine-Yaghmour
(N)
Ariel Ginzberg
(A)
Ibrahim Kassis
(I)
Michelle Halimi
(M)
Keren Regev
(K)
Hadar Kolb
(H)
Ifat Vigiser
(I)
Yoav Piora
(Y)
Irina Komarov
(I)
Avigail Hindi
(A)
Adi Wilf-Yarkoni
(A)
Itay Lotan
(I)
Elia Uri
(E)
Shaher Rotem
(S)
Hila Cohen
(H)
Informations de copyright
Copyright © 2022 Milo, Staun-Ram, Karussis, Karni, Hellmann, Bar-Haim, Miller and The Israeli Neuroimmunology Study Group on COVID-19 Vaccination in Multiple Sclerosis.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet. 2021 Jun 19;397(10292):2331-2333
pubmed: 34090624
Mult Scler Relat Disord. 2021 Nov;56:103251
pubmed: 34571415
Neurology. 2022 Feb 1;98(5):e541-e554
pubmed: 34810244
Mult Scler. 2021 May;27(6):864-870
pubmed: 33856242
EBioMedicine. 2021 Nov;73:103636
pubmed: 34666226
CNS Drugs. 2021 Mar;35(3):317-330
pubmed: 33743151
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Ann Neurol. 2021 Apr;89(4):780-789
pubmed: 33480077
Clin Med (Lond). 2021 Jan;21(1):e84-e87
pubmed: 33144402
Neurol Neuroimmunol Neuroinflamm. 2021 Nov 9;9(1):
pubmed: 34753828
Front Immunol. 2021 Apr 15;12:633184
pubmed: 33936045
Front Immunol. 2021 Sep 27;12:755333
pubmed: 34646278
J Neurol Sci. 2020 Nov 15;418:117147
pubmed: 32980780
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835
pubmed: 34035836
Lancet Rheumatol. 2021 Nov;3(11):e778-e788
pubmed: 34396154
Neurol Sci. 2021 Sep;42(9):3523-3526
pubmed: 34128150
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
EBioMedicine. 2021 Oct;72:103581
pubmed: 34563483
Nat Med. 2021 Nov;27(11):1990-2001
pubmed: 34522051
Vaccines (Basel). 2021 Dec 11;9(12):
pubmed: 34960216
Womens Health (Lond). 2021 Jan-Dec;17:17455065211022262
pubmed: 34096383
JAMA Neurol. 2021 Dec 1;78(12):1510-1514
pubmed: 34554197
J Neurol. 2022 Jan;269(1):39-43
pubmed: 34189719
Ann Intern Med. 2021 Jun;174(6):811-821
pubmed: 33721517
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
J Neuroimmunol. 2022 Jan 15;362:577788
pubmed: 34922128
Mult Scler Relat Disord. 2021 Apr;49:102777
pubmed: 33508573
Eur J Neurol. 2021 Nov;28(11):3742-3748
pubmed: 34288285
Vaccines (Basel). 2021 Jan 28;9(2):
pubmed: 33525459
Rev Neurol (Paris). 2021 Dec;177(10):1237-1240
pubmed: 34172292